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No Evidence of a Drug-Drug Interaction Between Letermovir (MK-8228) and Mycophenolate Mofetil
WL Marshall1, C Badshah1, F Liu1, WK Kraft2, F Colon-Gonzalez1, A van Schanke3, J Udo de Haes4, B Kantesaria1, CR Cho1, E Hulskotte5, JR Butterton1, EE Marcantonio1
1Merck & Co., Inc., Kenilworth, NJ, USA; 2Thomas Jefferson University, Philadelphia, PA, USA; 3Quantitative Solutions B.V., Oss, The Netherlands; 4PRA Health Sciences, Zuidlaren, The Netherlands; 
5Astellas Pharma, Leiden, The Netherlands
Subjects and Methods
 • This was an open-label, fixed-sequence, single- and multiple-dose trial to characterize the pharmacokinetic interaction 
between letermovir and MPA in 14 healthy adult females
 • Eligible subjects received 1 g oral MMF on Days 1 and 12 and 480 mg oral once-daily letermovir on Day 5 and Days 
8-16. Blood samples for pharmacokinetic evaluation (after an 8-hour fast) were collected on Days 1, 5, 12, and 16
 • Pharmacokinetic sampling of plasma for MPA and for letermovir was obtained at prespecified time points
 • Safety assessments and monitoring were performed throughout the duration of the study
Figure 1. Study Design
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Subject Demographics
 • All 14 subjects enrolled in this trial were female subjects between the ages of 20 and 49 years at screening with a body 
mass index (BMI) of 20.1 to 31.9 kg/m2. The mean age of subjects was 32.3 years. In total, 10 subjects (71.4%) were 
black or African American and 4 (28.6%) were white. (*) One of the subjects who reported her race as black or African 
American also reported being of American Indian or Alaska Native descent (Table 1).
Table 1. Subject Characteristics
Number of Subjects 
N=14 
n (%)
Female 14 (100.0)
Age (yr) 32.3
Range 20 to 49
BMI (kg/m2), range 20.1 to 31.9
Race
Black or African American 10* (71.4)
White 4 (28.6)
Safety and Tolerability
 • Oral administration of 480 mg letermovir once daily was reasonably well tolerated by the healthy female subjects 
 • Drug-related AEs all belonged to the Gastrointestinal Disorders System Organ Class (8 subjects, 57.1%), except for one 
event of fatigue. All drug-related AEs were mild in intensity and were transient
 • The events of diarrhea (3 subjects; 21.4%) were all single events. Two subjects (14.3%) reported single events of 
abdominal pain starting 45 minutes to ~2 hours after dosing on Days 13 (concomitant with nausea) and 16 (concomitant 
with diarrhea), respectively, with a duration of less than 3 hours. Vomiting occurred in one subject (7.1%) on a single 
occasion (Day 11, ~30 minutes after dosing, duration <1 min). Nausea was reported by 6 subjects (42.9%) on one or 
more occasions between Day 5 and Day 15
 • Most gastrointestinal AEs occurred relatively shortly after dosing and were transient
 Letermovir (MK-8228) Pharmacokinetics
 • A mean concentration profile of 480 mg letermovir (MK-8228) alone was compared to the mean concentration profile of  
480 mg letermovir (MK-8228) when MMF was coadministered (Figure 2)
 • The mean letermovir plasma concentration-time profile reached its peak at 2 hours postdose on Days 5, 12, and 16. 
All subjects had quantifiable plasma letermovir concentrations at the last time point drawn: 24 hours postdose on Day 
12 and 72 hours postdose on Days 5 and 16. Mean trough concentrations ranged from 583 to 803 ng/mL, with %CV 
ranging from 43.1 to 67.2
 • Summary statistical comparison of PK parameters from subjects administered 480 mg letermovir (MK-8228) alone 
compared to 480 mg letermovir (MK-8228) when MMF is coadministered in Table 2
Figure 2 (A) Mean letermovir concentration (linear scale) vs time by treatment group (letermovir 
single dose on Day 5, letermovir multiple dose + MMF single dose on Day 12, and letermovir 
multiple dose on Day 16); Figure 2B (semi-log scale)
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Table 2. Letermovir pharmacokinetics post-480 mg multiple dosing alone (Day 16) or 
coadministered with a single dose of 1 g MMF (Day 12)
MPA PK Parameter
MMF + Letermovir 
N=14
Letermovir Alone 
N=14
MMF + Letermovir vs 
Letermovir Alone Pseudo 
Within 
Subject %CV
Geometric 
Mean 95% CI
Geometric 
Mean 95% CI GMR 90% CI
AUC0-24 (hr*ng/mL) 84,011 (61,722, 114,351) 71,482 (55,593, 91,911) 1.18 (1.04, 1.32) 4.74
Cmax (ng/mL) 14,497 (10,748, 19,553) 13,018 (10,721, 15,807) 1.11 (0.93, 1.34) 7.42
Tmax (hr) 2.0 (1.0, 3.0) 2.2 (1.0, 3.0) -- -- --
T1/2 (hr) -- -- 13.8 44.3 -- -- --
CI=confidence interval, PK=pharmacokinetics, CV=coefficient of variance, GMR=geometric least-squares mean ratio between treatments, 
MPA=mycophenolic acid, MMF=mycophenolate mofetil.
Back-transformed least-squares mean and CI was from linear mixed-effects model performed on natural log-transformed values.
Pseudo within-subject %CV = 100*sqrt[(σA2 + σB2 – 2*σAB)/2], where σA2  and σB2  are the estimated variances on the log scale for the 2 
treatment groups and σAB is the corresponding estimated covariance, each obtained from the linear mixed-effects model.
MPA Pharmacokinetics
 • Figure 3A presents the mean MPA concentration (linear scale) vs time plots with data separated by treatment (MMF 
single dose on Day 1 and MMF single dose + letermovir multiple dose on Day 12) in the pharmacokinetic population. 
Figure 3B presents these data on a semi-log scale for MPA
 • All subjects had no quantifiable predose concentrations of MPA on Day 1. The mean MPA plasma concentration-
time profile reached its peak at 0.5 hours postdose on Days 1 and 12. All subjects had quantifiable plasma MPA 
concentrations up to 36 hours postdose on both Day 1 and Day 12
Table 3. Summary of pharmacokinetic parameters of mycophenolic acid (MPA) following single-
dose administration of 1 g mycophenolate mofetil (MMF) (Day 1) alone or with 480 mg letermovir 
dosed to steady state (Day 12)
MPA PK Paramete
MMF + Letermovir 
N=14
MMF Alone 
N=14
MMF + Letermovir/ 
MMF Alone Pseudo 
Within 
Subject %CV
Geometric 
Mean 95% CI
Geometric 
Mean 95% CI GMR 90% CI
AUC0-∞ (hr*ng/mL) 68,131 (58,187, 79,775) 63,108 (53,152, 74,928) 1.08 (96.8, 120.4) 4.36
Cmax (ng/mL) 22,881 (18,520, 28,268) 23,858 (19,489, 29,207) 0.95 (81.9, 112.3) 6.29
Tmax (hr) 0.52 (0.5, 2.0) 0.52 (0.5, 2.0) -- -- --
T1/2 (hr) 13.1 42.6 13.3 27.2 -- -- --
CI=confidence interval, PK=pharmacokinetics, CV=coefficient of variance, GMR=geometric least-squares mean ratio between treatments, 
MPA=mycophenolic acid, MMF=mycophenolate mofetil.
Back-transformed least-squares mean and CI was from linear mixed-effects model performed on natural log-transformed values.
Pseudo within-subject %CV = 100*sqrt[(σA2 + σB2 – 2*σAB)/2], where σA2  and σB2  are the estimated variances on the log scale for the 2 
treatment groups and σAB is the corresponding estimated covariance, each obtained from the linear mixed-effects model.
Figure 3 (A) Mean MPA concentration (linear scale) vs time plots with data separated by treatment 
(MMF single dose on Day 1 and MMF single dose + letermovir multiple dose on Day 12) (B) Semi-
log scale
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Table 4. Accumulation (GMR%) and time linearity (GMR%) based on letermovir pharmacokinetic 
parameters in the pharmacokinetic population
PK Parameter
Day 5 
N=14
Day 16 
N=14
Accumulation Ratio 
(Day 16/Day 5)
Time Linearity (Day 16 
AUC0-24/Day 5 AUCinf)
AUC0-24 AUCinf AUC0-24
GMR 
(90% CI)
Pseudo 
Within 
Subject %CV
GMR 
(90% CI)
Pseudo 
Within 
Subject %CV
AUC (hr*ng/mL) 63,056 
(51,600, 77,057)
71,128 
(58,059, 87,140)
71,482 
(55,593, 91,911)
113.4 
(90.8, 141.5)
7.26 100.5 
(83.8, 120.5)
7.25
Cmax (ng/mL) 12,918 (10,725, 15,561) 13,018 
(10,721, 15,807)
100.8 
(79.6, 127.5)
7.71 NA NA
CI=confidence interval, CV=coefficient of variance, GMR=geometric least-squares mean ratio between treatments (expressed as a percent), 
SD=single dose, MD=multiple dose.
For Day 5 and Day 16, AUC0-24 and AUC0-∞ absolute values were back-transformed least-squares mean and 95% CI were from mixed-effects model 
performed on natural log-transformed values.
Geometric mean ratio (%) and 90% CI were from mixed-effects model performed on natural log-transformed values. Day 16 AUC0-24/Day 5 AUC0-24 
was used for ratio of AUCs.
Pseudo within-subject %CV=100*sqrt[(σA2 + σB2 – 2*σAB)/2], where σA2  and σB2  are the estimated variances on the log scale for the 2 treatment 
groups and σAB is the corresponding estimated covariance, each obtained from the linear mixed-effects model.
Discussion
Letermovir Pharmacokinetics
 • The estimated GMR and 90% confidence interval for the comparison (letermovir with MMF/letermovir alone) were 1.18 (1.04, 
1.32) for letermovir AUC0-24 and 1.11 (0.93, 1.34) for letermovir Cmax. The CI for AUC, but not Cmax, lay completely above 1, 
suggesting a small increase in letermovir exposure when dosed with MMF
 • Letermovir Tmax was about 2 hours whether administered alone or administered with MMF
 • The geometric mean linearity ratio (MD AUC0-24/SD AUC0-∞) and 90% CI for letermovir were 1.01 (0.84, 1.21), indicating 
consistency with linear kinetics (Table 4)
 • The geometric mean accumulation ratio and 90% CI for letermovir were 1.13 (0.91, 1.42) for AUC0-24 and 1.01 (0.80, 1.28) for 
Cmax (Table 4)
MPA Pharmacokinetics
 • The estimated GMR and 90% confidence interval for the comparison (MMF with letermovir/MMF alone) were 1.08 (0.96, 
1.21) for MPA AUC0-∞  and 0.96 (0.81, 1.13) for MPA Cmax. The GMRs were close to 1 and the confidence intervals included 1, 
suggesting that coadministration with letermovir had no effect on the single-dose PK of MPA
 • Median Tmax was the same whether MMF was administered with letermovir or administered alone (0.52 hr), as was terminal 
half-life (geometric mean ~13 hr)
Conclusions
 ● Multiple-dose administration of 480 mg letermovir daily with a single dose of 1 g MMF 
was generally well tolerated by the healthy subjects in this study
 ● Coadministration of letermovir and MMF had no clinically meaningful effect on the PK 
of letermovir or MPA
 ● Letermovir and MMF may be coadministered without dose adjustment
ResultsBackground
 • Letermovir (MK-8228) belongs to a new class 
(terminase inhibitors) of anticytomegalovirus (CMV) 
agents and is a once-daily inhibitor in development 
to prevent CMV infection and disease in transplant 
patients
 • Mycophenolate mofetil (MMF) is indicated for 
prophylaxis of organ rejection in patients receiving 
allogeneic renal, cardiac, or hepatic transplants and 
is likely to be used as comedication in transplant 
patients
 • Mycophenolic acid (MPA), the active metabolite 
of MMF, is metabolized by several glucuronyl 
transferases (UGT1A7/8/9/10 and UGT2B7), 
CYP3A4/5, and CYP2C8 and is a substrate of 
the transporters OATP1B1 and 1B3 and the 
P-glycoprotein (P-gp). Letermovir is an inhibitor 
of CYP3A4 and CYP2C8 as well as OATP1B1, 
OATP1B3, and possibly P-gp. Thus, concentrations 
of MPA may potentially increase with letermovir 
coadministration
 • This trial investigated the potential effect of 
letermovir on MPA pharmacokinetics and also 
explored potential effects of MMF/MPA on letermovir 
pharmacokinetics
Aims
 • To determine the effect of letermovir at steady state 
on the pharmacokinetic parameters of MPA following 
coadministration of a single dose of MMF to healthy 
female subjects. PK parameters included AUC0-inf, 
Cmax, Tmax, and apparent terminal t1/2
 • To determine the effect of a single dose of MMF 
on the steady-state pharmacokinetic parameters of 
letermovir in healthy female subjects. Parameters 
included AUC0-24, Cmax, Tmax, and apparent terminal 
t1/2
Abstract  
Introduction: Letermovir (MK-8228) is a potent, once-
daily inhibitor of the cytomegalovirus (CMV) terminase 
complex that is being developed for the prophylaxis of 
CMV infection in transplant patients. This study evaluated 
the pharmacokinetic interactions, safety, and tolerability 
of letermovir when coadministered in healthy subjects with 
mycophenolate mofetil (MMF), which is the morpholinoethyl 
ester prodrug of mycophenolic acid (MPA).
Methods: This was an open-label trial in 14 healthy female 
subjects that explored the pharmacokinetic parameters of a 
single 1 g oral dose of MMF administered alone on Day 1 
and coadministered on Day 12 with 480 mg oral once-daily 
letermovir given on Day 5 and from Day 8 continued through 
Day 16. Letermovir PK was assessed at single dose (Day 
5) and at steady state on Day 12 (with MMF) and Day 16 
(alone following MMF washout).
Results: Coadministration of 480 mg qd letermovir at 
steady state with a single dose of 1 g of MMF had no 
effect on the pharmacokinetics of MPA. The MPA AUC0-inf 
and Cmax geometric mean ratios (GMRs) [90% confidence 
interval] for the comparison (MMF with letermovir/
MMF alone) were 1.08 [0.96, 1.21] and 0.96 [0.81, 1.13], 
respectively. Coadministration of a single dose of 1 g MMF 
with 480 mg qd letermovir at steady state had no clinically 
meaningful effect on the pharmacokinetics of letermovir, 
with AUC0-24 and Cmax GMR of 1.18 [1.04, 1.32] and 1.11 
[0.93, 1.34], respectively. The letermovir geometric mean 
accumulation ratio (Day 16/Day 5) and 95% CI were 
1.13 [0.90, 1.42] for AUC0-24 and 1.01 [0.79, 1.28] for Cmax, 
indicating that accumulation of letermovir when administered 
as daily doses is minimal. All related AEs were reported as 
mild in severity and resolved. 
Conclusions: Multiple-dose administration of 480 mg 
letermovir daily with a single dose of 1 g MMF was 
generally well tolerated by the healthy subjects in this 
study. Coadministration of letermovir and MMF had no 
clinically meaningful effect on the PK of letermovir or MPA. 
Letermovir and MMF may be coadministered without dose 
adjustment.
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